S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
Bibliographic record
Abstract
Background: Vaso-occlusive crises (VOCs) are a key characteristic of sickle cell disease (SCD). Safety and efficacy of crizanlizumab from 26-week analysis of SOLACE-kids study in 50 children with SCD aged 12 to <18 years were reported at ASH 2021. Safety and tolerability of the confirmed dose (5 mg/kg) of crizanlizumab in these children were consistent with the established profile in adults from the SUSTAIN study. Crizanlizumab also showed a reduction in the median annualized rate of VOCs compared to baseline. Aims: To confirm and establish appropriate dosing for different pediatric age groups (Part A), and to evaluate the safety and efficacy of the confirmed dose of crizanlizumab (Part B), in additional pediatric patients with SCD (ClinicalTrials.gov: NCT03474965; EudraCT: 2017-001747-12). Methods: SOLACE-kids is an ongoing Phase 2 study conducted in children with SCD (any genotype) and a history of ≥1 VOC leading to a healthcare visit within 12 months prior to screening. Eligible patients are grouped by age: Group 1 (12 to <18 years), Group 2 (6 to <12 years), and Group 3 (6 months to <6 years). Patients received crizanlizumab on Day 1, Day 15, then every 4 weeks (up to 2 years), with or without hydroxyurea (HU)/Hydroxycarbamide (HC). This analysis reports updated pharmacokinetics (PK)/pharmacodynamics (PD; ex vivo P-selectin inhibition), safety, and efficacy results for patients in Group 1 who received crizanlizumab 5 mg/kg IV for 2 years. Results: As of 05 May 2022, of 50 patients enrolled in Group 1 (median [range] age 14.9 [12.0–17.9] years; 58% female; 88% HbSS genotype; 64% Black/African American; 84% receiving HU), 33 (66%) completed treatment with crizanlizumab. Median (Q1-Q3) duration of crizanlizumab exposure was 106.1 (94.9–107) weeks; 86% and 56% of patients received treatment for ≥54 and ≥106 weeks, respectively. Eleven patients’ data were evaluated for PK/PD analysis. The mean area under the curve from time zero to the last measurable concentration after the first infusion (AUCd15) and after multiple doses at steady state (AUCtau) was 10500 and 15800 hr*μg/mL, respectively. The mean maximum serum concentrations (Cmax) after the first infusion (80.5 μg/ml) and at steady state (95.6 μg/mL), indicated no significant accumulation of crizanlizumab. At steady state, the mean apparent elimination half-life (T1/2) was 10.3 days. The mean P-selectin inhibition ranged from 98.7% to 100% at a first dose and from 88.6% to 97.6% at the steady-state dose. Overall, 47 (94%) patients reported ≥1 adverse event (AEs), most commonly with headache (38%). Treatment-related AEs occurred in 15 (30%) patients, of which infusion-related reaction (10%) and nausea (6%) were most common. Grade ≥3 AEs occurred in 24 (48%), of which back pain and pain in extremity in 1 patient and increased bilirubin in 1 patient were related to crizanlizumab. None of the serious AEs or AEs leading to discontinuation (including one death due to bacterial meningitis), dose change, and/or interruption were deemed related to crizanlizumab per the investigator. None of these patients developed antibodies against crizanlizumab. The impact of crizanlizumab on annualized rate of VOCs is summarized in Table. Summary/Conclusion: In this 2-year analysis, crizanlizumab 5 mg/kg with or without concomitant HU/HC has shown a reduction in VOCs resulting in decreased healthcare visits per year, consistent with the established profile of crizanlizumab in adults. Crizanlizumab was safe and well tolerated with no new/unexpected safety concerns. These results confirm 5 mg/kg as an adequate dose in pediatrics with SCD aged 12 to <18 years.Keywords: Sickle cell disease, Vasoocclusive crisis, P-selectin, Pediatric
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".